Literature DB >> 23278573

Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial.

Michael Benatar1, Donald B Sanders, Gil I Wolfe, Michael P McDermott, Rabi Tawil.   

Abstract

Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) is a multicenter, randomized, double blind, placebo-controlled trial that is being conducted under the auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23278573     DOI: 10.1111/j.1749-6632.2012.06780.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.

Authors:  Michael Benatar; Michael P Mcdermott; Donald B Sanders; Gil I Wolfe; Richard J Barohn; Richard J Nowak; Michael Hehir; Vern Juel; Hans Katzberg; Rabi Tawil
Journal:  Muscle Nerve       Date:  2016-01-27       Impact factor: 3.217

Review 2.  Myasthenia gravis - autoantibody characteristics and their implications for therapy.

Authors:  Nils Erik Gilhus; Geir Olve Skeie; Fredrik Romi; Konstantinos Lazaridis; Paraskevi Zisimopoulou; Socrates Tzartos
Journal:  Nat Rev Neurol       Date:  2016-04-22       Impact factor: 42.937

Review 3.  Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis.

Authors:  Kai Zhu; Jiaoxing Li; Xin Huang; Wei Xu; Weibin Liu; Jiaxin Chen; Pei Chen; Huiyu Feng
Journal:  Neurol Sci       Date:  2017-07-13       Impact factor: 3.307

4.  Learning from the past: reflections on recently completed myasthenia gravis trials.

Authors:  Michael Benatar; James F Howard; Richard Barohn; Gil I Wolfe; Gary Cutter
Journal:  Ann N Y Acad Sci       Date:  2017-10-24       Impact factor: 5.691

5.  Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.

Authors:  Sean M Gratton; Angela M Herro; William J Feuer; Byron L Lam
Journal:  J Neuroophthalmol       Date:  2016-03       Impact factor: 3.042

6.  Ocular myasthenia gravis: controversies and updates.

Authors:  Sui H Wong; Saif Huda; Angela Vincent; Gordon T Plant
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

7.  Ophthalmologic manifestations in myasthenia gravis: presentation and prognosis.

Authors:  Onur Akan; Leyla Baysal-Kirac
Journal:  Acta Neurol Belg       Date:  2021-01-04       Impact factor: 2.396

8.  Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients.

Authors:  Carl Johan Molin; Elisabet Westerberg; Anna Rostedt Punga
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

9.  Keep an eye out for myasthenia gravis patients with an eye out.

Authors:  A Arturo Leis; Alan R Moore
Journal:  Front Neurol       Date:  2014-07-01       Impact factor: 4.003

Review 10.  Myasthenia gravis: a clinical-immunological update.

Authors:  Sophie Binks; Angela Vincent; Jacqueline Palace
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.